These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 35994500)

  • 21. High SARS-CoV-2 Seroprevalence in Rural Peru, 2021: a Cross-Sectional Population-Based Study.
    Moreira-Soto A; Pachamora Diaz JM; González-Auza L; Merino Merino XJ; Schwalb A; Drosten C; Gotuzzo E; Talledo M; Arévalo Ramirez H; Peralta Delgado R; Bocanegra Vargas S; Drexler JF
    mSphere; 2021 Dec; 6(6):e0068521. PubMed ID: 34817236
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Seroprevalence of SARS-CoV-2 antibodies and associated risk factors in children less than 6 years of age in the canton of Fribourg, Switzerland (COVPED study): a population-based cross-sectional study.
    Rouge Elton PA; Schmitt PA; Faouzi M; Zimmermann P; Ritter Schenk C
    Swiss Med Wkly; 2022 May; 152():w30173. PubMed ID: 35748747
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Seroprevalence of anti-SARS-CoV-2 IgG/IgM antibodies in Borgosesia (Piedmont Region, Northern Italy) population: a surveillance strategy in post-lockdown period?].
    Alessi D; Borré S; Barale A; Isabella A; Milano F; Rossi MA; Silano V; Piu N; Cena T; Faggiano F;
    Epidemiol Prev; 2020; 44(5-6 Suppl 2):200-206. PubMed ID: 33412811
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Assessment of initial SARS-CoV-2 seroprevalence in the most affected districts in the municipality of São Paulo, Brazil.
    Tess BH; Granato CFH; Alves MCGP; Pintão MCT; Nunes MC; Rizzatti EG; Reinach FC
    Braz J Infect Dis; 2021; 25(4):101604. PubMed ID: 34416142
    [TBL] [Abstract][Full Text] [Related]  

  • 25. SARS-CoV-2 antibody seroprevalence in Togo: a national cross-sectional household survey, May-June, 2021.
    Konu YR; Condé S; Gbeasor-Komlanvi F; Sadio AJ; Tchankoni MK; Anani J; Bitty-Anderson A; Mirindi BR; Diallo FBT; MIjiyawa M; Dagnra AC; Ekouevi DK
    BMC Public Health; 2022 Dec; 22(1):2294. PubMed ID: 36476149
    [TBL] [Abstract][Full Text] [Related]  

  • 26. SARS-CoV-2 seroprevalence in Portugal following the third epidemic wave: results of the second National Serological Survey (ISN2COVID-19).
    Kislaya I; Gonçalves P; Gómez V; Gaio V; Roquette R; Barreto M; Sousa-Uva M; Torres AR; Santos J; Matos R; Manita C; Almeida Santos J; Soeiro S; de Sousa R; Costa I; Verdasca N; Guiomar R; Rodrigues AP;
    Infect Dis (Lond); 2022 Jun; 54(6):418-424. PubMed ID: 35023439
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cumulative Incidence of SARS-CoV-2 Infections Among Adults in Georgia, United States, August to December 2020.
    Chamberlain AT; Toomey KE; Bradley H; Hall EW; Fahimi M; Lopman BA; Luisi N; Sanchez T; Drenzek C; Shioda K; Siegler AJ; Sullivan PS
    J Infect Dis; 2022 Feb; 225(3):396-403. PubMed ID: 34662409
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Seroprevalence of antibodies against SARS-CoV-2 in the adult population during the pre-vaccination period, Norway, winter 2020/21.
    Anda EE; Braaten T; Borch KB; Nøst TH; Chen SLF; Lukic M; Lund E; Forland F; Leon DA; Winje BA; Kran AB; Kalager M; Johansen FL; Sandanger TM
    Euro Surveill; 2022 Mar; 27(13):. PubMed ID: 35362405
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Seroprevalence of SARS-CoV-2 antibody among urban Iranian population: findings from the second large population-based cross-sectional study.
    Zamani M; Poustchi H; Mohammadi Z; Dalvand S; Sharafkhah M; Motevalian SA; Eslami S; Emami A; Somi MH; Yazdani-Charati J; Saki N; Karami M; Najafi F; Mohebbi I; Veisi N; Hormati A; Pourfarzi F; Ghadimi R; Ansari-Moghaddam A; Sharifi H; Roshandel G; Mansour-Ghanaei F; Joukar F; Shayanrad A; Eghtesad S; Niavarani A; Delavari A; Kaveh S; Feizesani A; Markarian M; Shafighian F; Sadjadi A; Darvishian M; Malekzadeh R
    BMC Public Health; 2022 May; 22(1):1031. PubMed ID: 35606743
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Enhanced surveillance of COVID-19 in Scotland: population-based seroprevalence surveillance for SARS-CoV-2 during the first wave of the epidemic.
    Dickson E; Palmateer NE; Murray J; Robertson C; Waugh C; Wallace LA; Mathie L; Heatlie K; Mavin S; Gousias P; Von Wissman B; Goldberg DJ; McAuley A
    Public Health; 2021 Jan; 190():132-134. PubMed ID: 33453689
    [TBL] [Abstract][Full Text] [Related]  

  • 31. SARS-CoV-2 antibody prevalence and correlates of six ethnic groups living in Amsterdam, the Netherlands: a population-based cross-sectional study, June-October 2020.
    Coyer L; Boyd A; Schinkel J; Agyemang C; Galenkamp H; Koopman ADM; Leenstra T; Moll van Charante EP; van den Born BH; Lok A; Verhoeff A; Zwinderman AH; Jurriaans S; van Vught LA; Stronks K; Prins M
    BMJ Open; 2022 Jan; 12(1):e052752. PubMed ID: 34992110
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prevalence of SARS-CoV-2 IgG antibodies in an area of northeastern Italy with a high incidence of COVID-19 cases: a population-based study.
    Stefanelli P; Bella A; Fedele G; Pancheri S; Leone P; Vacca P; Neri A; Carannante A; Fazio C; Benedetti E; Fiore S; Fabiani C; Simmaco M; Santino I; Zuccali MG; Bizzarri G; Magnoni R; Benetollo PP; Merler S; Brusaferro S; Rezza G; Ferro A
    Clin Microbiol Infect; 2021 Apr; 27(4):633.e1-633.e7. PubMed ID: 33253941
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prevalence of SARS-CoV-2 antibodies in hemodialysis patients in Senegal: a multicenter cross-sectional study.
    Seck SM; Mbow M; Kane Y; Cisse MM; Faye G; Kama A; Sarr M; Nitcheu P; Dahaba M; Diallo IM; Diawara MS; Latou LNM; Dia Y; Mboup S
    BMC Nephrol; 2021 Nov; 22(1):384. PubMed ID: 34789170
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Disparities in Seroprevalence of SARS-CoV-2 Immunoglobulin Antibodies in a Large Midwestern Health Care System.
    Fitzpatrick V; Rivelli A; Blair C; Copeland K; Richards J
    Public Health Rep; 2021 May; 136(3):361-367. PubMed ID: 33673779
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Seroprevalence of Unidentified SARS-CoV-2 Infection in Hong Kong During 3 Pandemic Waves.
    Boon SS; Wong MCS; Ng RWY; Leung DTM; Chen Z; Lai CKC; Ho WCS; Huang J; Wong BKC; Fung KSC; Chan PKS
    JAMA Netw Open; 2021 Nov; 4(11):e2132923. PubMed ID: 34779848
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Serological survey for SARS-CoV-2 antibodies among tribal communities of Odisha post-second wave.
    Kshatri JS; Bhattacharya D; Giri S; Palo SK; Kanungo S; Mansingh A; Parai D; Dany SS; Bisoyee A; Choudhary HR; Sinha A; Sahoo RK; Bhoi T; Mohanta AR; Ota AB; Mohanty B; Sahoo UK; Pati S
    Indian J Med Res; 2022 Aug; 156(2):284-290. PubMed ID: 36629188
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Strategies to Estimate Prevalence of SARS-CoV-2 Antibodies in a Texas Vulnerable Population: Results From Phase I of the Texas Coronavirus Antibody Response Survey.
    Valerio-Shewmaker MA; DeSantis S; Swartz M; Yaseen A; Gonzalez MO; Kohl HWI; Kelder SH; Messiah SE; Aguillard KA; Breaux C; Wu L; Shuford J; Pont S; Lakey D; Boerwinkle E
    Front Public Health; 2021; 9():753487. PubMed ID: 34970525
    [No Abstract]   [Full Text] [Related]  

  • 38. High Community SARS-CoV-2 Antibody Seroprevalence in a Ski Resort Community, Blaine County, Idaho, US. Preliminary Results.
    McLaughlin CC; Doll MK; Morrison KT; McLaughlin WL; O'Connor T; Sholukh AM; Bossard EL; Phasouk K; Ford ES; Diem K; Klock AM; Jerome KR; Corey L
    medRxiv; 2020 Jul; ():. PubMed ID: 32743610
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Seroprevalence of anti-SARS-CoV-2 IgG antibodies in the staff of a public school system in the midwestern United States.
    Lopez L; Nguyen T; Weber G; Kleimola K; Bereda M; Liu Y; Accorsi EK; Skates SJ; Santa Maria JP; Smith KR; Kalinich M
    PLoS One; 2021; 16(6):e0243676. PubMed ID: 34111144
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Estimation of US SARS-CoV-2 Infections, Symptomatic Infections, Hospitalizations, and Deaths Using Seroprevalence Surveys.
    Angulo FJ; Finelli L; Swerdlow DL
    JAMA Netw Open; 2021 Jan; 4(1):e2033706. PubMed ID: 33399860
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.